Jade Biosciences (JBIO) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $7.69 to $8.08
• 50-Day Range: $6.77 to $11.14
• 52-Week Range: $6.57 to $105.00
• Volume: 31,880 shs
• Average Volume: 164,196 shs
• Market Capitalization: $262.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Jade Biosciences Stock Analysis - MarketRank™

Jade Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 620th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Jade Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Jade Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Jade Biosciences is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jade Biosciences is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jade Biosciences has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for JBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jade Biosciences does not currently pay a dividend.

Dividend Growth

Jade Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for JBIO.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: -0.34

News Sentiment

Jade Biosciences has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Jade Biosciences this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for JBIO on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Jade Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.90% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

JBIO Stock Analysis - Frequently Asked Questions

How have JBIO shares performed this year?

Jade Biosciences' stock was trading at $7.06 at the start of the year. Since then, JBIO stock has increased by 13.5% and is now trading at $8.01.

How were Jade Biosciences' earnings last quarter?

Jade Biosciences, Inc. (NASDAQ:JBIO) announced its earnings results on Wednesday, August, 13th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.43.

Who are Jade Biosciences' major shareholders?

Top institutional shareholders of Jade Biosciences include Frazier Life Sciences Management L.P. (210.97%), Versant Venture Management LLC (181.43%), Soleus Capital Management L.P. (94.85%) and Geode Capital Management LLC (80.43%).

How do I buy shares of Jade Biosciences?

Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JBIO
• Previous Symbol: NASDAQ:JBIO
• CIK: 1798749
• Web: N/A
• Phone: (617) 443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jade Biosciences: $16.00
• High Price Target: $18.00
• Low Price Target: $14.00
• Potential Upside/Downside: +108.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($30.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.96%
• Return on Assets: -47.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.31
• Quick Ratio: 10.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $92.88 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 32,630,000
• Free Float: 24,503,000
• Market Cap: $250.92 million
• Optionable: N/A
• Beta: 1.03